Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Results of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised part III examine: 5-year evaluation of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V. Recurrent glioblastoma: from molecular panorama to new therapy views. Cancers. Cancers. 2020;13:47.
Vymazal J, Kazda T, Novak T, Slanina P, Sroubek J, Klener J, et al. Eighteen years’ expertise with tumor treating fields within the therapy of newly recognized glioblastoma. Entrance Oncol. 2022;12:1014455.
Stupp R, Taillibert S, Kanner A, Learn W, Steinberg D, Lhermitte B, et al. Impact of tumor-treating fields plus upkeep temozolomide vs upkeep temozolomide alone on survival in sufferers with glioblastoma: a randomized scientific trial. JAMA. 2017;318:2306–16.
Xu R, Wang F, Yang H, Wang Z. Motion websites and scientific software of HIF-1alpha inhibitors. Molecules. 2022;27:3426.
Albadari N, Deng S, Li W. The transcriptional elements HIF-1 and HIF-2 and their novel inhibitors in most cancers remedy. Skilled Opin Drug Discov. 2019;14:667–82.
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, et al. Attenuating hypoxia pushed malignant habits in glioblastoma with a novel hypoxia-inducible issue 2 alpha inhibitor. Sci Rep. 2020;10:15195.
Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, et al. A small-molecule antagonist of HIF2alpha is efficacious in preclinical fashions of renal cell carcinoma. Most cancers Res. 2016;76:5491–500.
Gainer JL. Trans-sodium crocetinate for treating hypoxia/ischemia. Skilled Opin Investig Medicine. 2008;17:917–24.
Colapietro A, Mancini A, Vitale F, Martellucci S, Angelucci A, Llorens S. et al. Crocetin extracted from saffron exhibits antitumor results in fashions of human glioblastoma. Int J Mol Sci. 2020;21:423.
Shah HM, Jain AS, Joshi SV, Kharkar PS. Crocetin and associated oxygen diffusion-enhancing compounds: evaluation of chemical synthesis, pharmacology, scientific improvement, and novel therapeutic purposes. Drug Dev Res. 2021;82:883–95.
Sheehan J, Ionescu A, Pouratian N, Hamilton DK, Schlesinger D, Oskouian RJ Jr., et al. Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation: laboratory investigation. J Neurosurg. 2008;108:972–8.
Wong KH, Xie Y, Huang X, Kadota Ok, Yao XS, Yu Y, et al. Delivering crocetin throughout the blood-brain barrier through the use of gamma-cyclodextrin to deal with Alzheimer’s illness. Sci Rep. 2020;10:3654.
Duarte CD, Greferath R, Nicolau C, Lehn JM. myo-Inositol trispyrophosphate: a novel allosteric effector of hemoglobin with excessive permeation selectivity throughout the pink blood cell plasma membrane. Chembiochem. 2010;11:2543–8.
Grgic I, Tschanz F, Borgeaud N, Gupta A, Clavien PA, Guckenberger M, et al. Tumor oxygenation by myo-inositol trispyrophosphate enhances radiation response. Int J Radiat Oncol Biol Phys. 2021;110:1222–33.
Tran LB, Cao-Pham TT, Jordan BF, Deschoemaeker S, Heyerick A, Gallez B. Influence of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour fashions. J Cell Mol Med. 2019;23:1908–16.
Fornvik Ok, Zolfaghari S, Salford LG, Redebrandt HN. ITPP therapy of RG2 glioblastoma in a rat mannequin. Anticancer Res. 2016;36:5751–5.
Iyengar S, Schwartz D. Failure of inositol trispyrophosphate to boost extremely efficient radiotherapy of GL261 glioblastoma in mice. Anticancer Res. 2017;37:1121–5.
El Hafny-Rahbi B, Brodaczewska Ok, Collet G, Majewska A, Klimkiewicz Ok, Delalande A, et al. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia within the microenvironment and promotes antitumor immune response. J Cell Mol Med. 2021;25:3284–99.
Grzymajlo Ok, El Hafny-Rahbi B, Kieda C. Tumour suppressor PTEN exercise is differentially inducible by myo-inositol phosphates. J Cell Mol Med. 2023;27:879–90.
Miranda-Goncalves V, Cardoso-Carneiro D, Valbom I, Cury FP, Silva VA, Granja S, et al. Metabolic alterations underlying Bevacizumab remedy in glioblastoma cells. Oncotarget. 2017;8:103657–70.
Garcia-Romero N, Palacin-Aliana I, Madurga R, Carrion-Navarro J, Esteban-Rubio S, Jimenez B, et al. Bevacizumab dose adjustment to enhance scientific outcomes of glioblastoma. BMC Med. 2020;18:142.
Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, et al. Autocrine regulation of glioblastoma cell cycle development, viability and radioresistance via the VEGF-VEGFR2 (KDR) interaction. Cell Cycle. 2008;7:2553–61.
Lee J, Kim E, Ryu SW, Choi C, Choi Ok. Mixed inhibition of vascular endothelial progress issue receptor signaling with temozolomide enhances cytotoxicity towards human glioblastoma cells by way of downregulation of Neuropilin-1. J Neurooncol. 2016;128:29–34.
Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in improvement for glioblastoma and different malignancies. Future Oncol. 2011;7:339–54.
Liu Z, Han L, Dong Y, Tan Y, Li Y, Zhao M, et al. EGFRvIII/integrin beta3 interplay in hypoxic and vitronectinenriching microenvironment promote GBM development and metastasis. Oncotarget. 2016;7:4680–94.
Zhao YZ, Lin Q, Wong HL, Shen XT, Yang W, Xu HL, et al. Glioma-targeted remedy utilizing Cilengitide nanoparticles mixed with UTMD enhanced supply. J Management Launch. 2016;224:112–25.
Torrisi F, Minafra L, Cammarata FP, Savoca G, Calvaruso M, Vicario N. et al. SRC tyrosine kinase inhibitor and X-rays mixed impact on glioblastoma cell traces. Int J Mol Sci. 2020;21:3917.
Nesovic M, Divac Rankov A, Podolski-Renic A, Nikolic I, Tasic G, Mancini A, et al. Src inhibitors pyrazolo[3,4-d]pyrimidines, Si306 and Professional-Si306, inhibit focal adhesion kinase and suppress human glioblastoma invasion in vitro and in vivo. Cancers. 2020;12:1570.
Fallacara AL, Zamperini C, Podolski-Renic A, Dinic J, Stankovic T, Stepanovic M, et al. A brand new technique for glioblastoma therapy: in vitro and in vivo preclinical characterization of Si306, a pyrazolo[3,4-d]pyrimidine twin Src/P-glycoprotein inhibitor. Cancers. 2019;11:848.
Pham Ok, Luo D, Siemann DW, Regulation BK, Reynolds BA, Hothi P, et al. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFbetaR signaling-dependent method. Most cancers Lett. 2015;360:60–7.
Hadizadeh M, AminJafari A, Parvizpour S, Ghasemi S. Novel targets to beat antiangiogenesis remedy resistance in glioblastoma multiforme: Techniques biology strategy and suggestion of remedy by galunisertib. Cell Biol Int. 2022;46:1649–60.
Liu CC, Wu CL, Lin MX, Sze CI, Gean PW. Disulfiram sensitizes a therapeutic-resistant glioblastoma to the TGF-beta receptor inhibitor. Int J Mol Sci. 2021;22:10496.
Zhu Y, Liu X, Zhao P, Zhao H, Gao W, Wang L. Celastrol suppresses glioma vasculogenic mimicry formation and angiogenesis by blocking the PI3K/Akt/mTOR signaling pathway. Entrance Pharm. 2020;11:25.
Park JH, Kim MJ, Kim WJ, Kwon KD, Ha KT, Choi BT, et al. Isolinderalactone suppresses human glioblastoma progress and angiogenic exercise in 3D microfluidic chip and in vivo mouse fashions. Most cancers Lett. 2020;478:71–81.
Wang C, Chen Y, Wang Y, Liu X, Liu Y, Li Y, et al. Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma via ceRNA impact of miR-194-5p and lncRNA NEAT1. J Exp Clin Most cancers Res. 2019;38:371.
Wang W, Li T, Cheng Y, Li F, Qi S, Mao M. et al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Most cancers Cell. 2024;42:815–832.
Mudassar F, Shen H, O’Neill G, Hau E. Focusing on tumor hypoxia and mitochondrial metabolism with anti-parasitic medicine to enhance radiation response in high-grade gliomas. J Exp Clin Most cancers Res. 2020;39:208.
Takabe H, Warnken ZN, Zhang Y, Davis DA, Smyth HDC, Kuhn JG, et al. A repurposed drug for mind most cancers: enhanced atovaquone amorphous stable dispersion by combining a spontaneously emulsifying part with a polymer service. Pharmaceutics. 2018;10:60.
Chen C, Liang H, Qin R, Li X, Wang L, Du S, et al. Doramectin inhibits glioblastoma cell survival by way of regulation of autophagy in vitro and in vivo. Int J Oncol. 2022;60:29.
Music D, Liang H, Qu B, Li Y, Liu J, Zhang Y, et al. Ivermectin inhibits the expansion of glioma cells by inducing cell cycle arrest and apoptosis in vitro and in vivo. J Cell Biochem. 2019;120:622–33.
Liu Y, Fang S, Solar Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, progress and survival of glioblastoma via inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016;480:415–21.
Lo Dico A, Valtorta S, Ottobrini L, Moresco RM. Function of metformin and AKT axis modulation within the reversion of hypoxia induced TMZ-resistance in glioma cells. Entrance Oncol. 2019;9:463.
Calvo Tardon M, Marinari E, Migliorini D, Bes V, Tankov S, Charrier E. et al. An experimentally outlined hypoxia gene signature in glioblastoma and its modulation by metformin. Biology. 2020;9:264.
Feng SW, Chang PC, Chen HY, Hueng DY, Li YF, Huang SM. Exploring the mechanism of adjuvant therapy of glioblastoma utilizing temozolomide and metformin. Int J Mol Sci. 2022;23:8171.
Friedl AA, Prise KM, Butterworth KT, Montay-Gruel P, Favaudon V. Radiobiology of the FLASH impact. Med Phys. 2022;49:1993–2013.
Leavitt RJ, Almeida A, Grilj V, Montay-Gruel P, Godfroid C, Petit B, et al. Acute hypoxia doesn’t alter tumor sensitivity to FLASH radiation remedy. Int J Radiat Oncol Biol Phys. 2024;S0360-3016:00320-1.
Park S, Avera AD, Kim Y. Biomanufacturing of glioblastoma organoids exhibiting hierarchical and spatially organized tumor microenvironment by way of transdifferentiation. Biotechnol Bioeng. 2022;119:3252–74.
Tejero R, Huang Y, Katsyv I, Kluge M, Lin JY, Tome-Garcia J, et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with area of interest microenvironment. EBioMedicine. 2019;42:252–69.
Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient-derived glioblastoma organoid mannequin and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180:188–204.e22.
Zhang W, Cao L, Yang J, Zhang S, Zhao J, Shi Z. et al. AEP-cleaved DDX3X induces various RNA splicing occasions to mediate most cancers cell adaptation in harsh microenvironments. J Clin Make investments. 2023;134:e173299.
Nicholson JG, Cirigliano S, Singhania R, Haywood C, Shahidi Dadras M, Yoshimura M, et al. Continual hypoxia remodels the tumor microenvironment to help glioma stem cell progress. Acta Neuropathol Commun. 2024;12:46.
Ogawa Ok, Ishiuchi S, Inoue O, Yoshii Y, Saito A, Watanabe T, et al. Section II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;82:732–8.
Yahara Ok, Ohguri T, Udono H, Yamamoto J, Tomura Ok, Onoda T, et al. Radiotherapy utilizing IMRT boosts after hyperbaric oxygen remedy with chemotherapy for glioblastoma. J Radiat Res. 2017;58:351–6.
Kohshi Ok, Yamamoto H, Nakahara A, Katoh T, Takagi M. Fractionated stereotactic radiotherapy utilizing gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol. 2007;82:297–303.
Arpa D, Parisi E, Ghigi G, Cortesi A, Longobardi P, Cenni P, et al. Function of hyperbaric oxygenation plus hypofractionated stereotactic radiotherapy in recurrent high-grade glioma. Entrance Oncol. 2021;11:643469.
Chen JR, Xu HZ, Ding JB, Qin ZY. Radiotherapy after hyperbaric oxygenation in malignant gliomas. Curr Med Res Opin. 2015;31:1977–84.
Lansdorp CA, van Hulst RA. Double-blind trials in hyperbaric medication: a story evaluation on previous experiences and concerns in designing sham hyperbaric therapy. Clin Trials. 2018;15:462–76.
Simon JM, Noel G, Chiras J, Hoang-Xuan Ok, Delattre JY, Baillet F, et al. Radiotherapy and chemotherapy with or with out carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiother Oncol. 2003;67:45–51.
Gainer JL, Sheehan JP, Larner JM, Jones DR. Trans sodium crocetinate with temozolomide and radiation remedy for glioblastoma multiforme. J Neurosurg. 2017;126:460–6.
Mertes PM, Collange O, Coliat P, Banerjee M, Diringer MC, Roche A, et al. Liposomal encapsulation of trans-crocetin enhances oxygenation in sufferers with COVID-19-related ARDS receiving mechanical air flow. J Management Launch. 2021;336:252–61.
Woods SD, Skinner RD, Ricca AM, Brown AT, Lowery JD, Borrelli MJ, et al. Progress in dodecafluoropentane emulsion as a neuroprotective agent in a rabbit stroke mannequin. Mol Neurobiol. 2013;48:363–7.
Lickliter JD, Ruben J, Kichenadasse G, Jennens R, Gzell C, Mason RP, et al. Dodecafluoropentane emulsion as a radiosensitizer in glioblastoma multiforme. Most cancers Res Commun. 2023;3:1607–14.
Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval abstract: bevacizumab (Avastin) as therapy of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131–8.
Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and together with irinotecan within the therapy of sufferers with recurrent glioblastoma multiforme. J Clin Neurosci. 2012;19:1636–40.
Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly recognized glioblastoma. N Engl J Med. 2014;370:2048–9.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly recognized glioblastoma. N Engl J Med. 2014;370:699–708.
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954–63.
Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Section II examine of bevacizumab plus temozolomide throughout and after radiation remedy for sufferers with newly recognized glioblastoma multiforme. J Clin Oncol. 2011;29:142–8.
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, et al. The addition of bevacizumab to plain radiation remedy and temozolomide adopted by bevacizumab, temozolomide, and irinotecan for newly recognized glioblastoma. Clin Most cancers Res. 2011;17:4119–24.
Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly recognized glioblastoma. N Engl J Med. 2014;370:2049.
Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, et al. Security and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in sufferers with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012;82:2018–24.
Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys. 2012;82:67–76.
Niyazi M, Jansen NL, Rottler M, Ganswindt U, Belka C. Recurrence sample evaluation after re-irradiation with bevacizumab in recurrent malignant glioma sufferers. Radiat Oncol. 2014;9:299.
Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougere C, et al. Re-irradiation and bevacizumab in recurrent high-grade glioma: an efficient therapy choice. J Neurooncol. 2014;117:337–45.
Antoni D, Jastaniah Z, Haoming QC, Gaultier C, Ahle G, Couchot J, et al. Patterns of relapse in sufferers with excessive grade glioma receiving mixed therapies together with stereotactic re-irradiation for a primary relapse. Most cancers Radiother. 2016;20:282–91.
She L, Su L, Liu C. Bevacizumab mixed with re-irradiation in recurrent glioblastoma. Entrance Oncol. 2022;12:961014.
Youland RS, Lee JY, Kreofsky CR, Brown PD, Uhm JH, Laack NN. Fashionable reirradiation for recurrent gliomas can safely delay tumor development. Neurooncol Pr. 2018;5:46–55.
Morris SL, Zhu P, Rao M, Martir M, Zhu JJ, Hsu S, et al. Gamma knife stereotactic radiosurgery together with bevacizumab for recurrent glioblastoma. World Neurosurg. 2019;127:e523–e33.
Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, et al. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in sufferers with recurrent high-grade gliomas: outcomes from a part I examine. Neuro Oncol. 2021;23:677–86.
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG oncology/RTOG1205: a randomized part II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as therapy for recurrent glioblastoma. J Clin Oncol. 2023;41:1285–95.
Witte HM, Riecke A, Steinestel Ok, Schulz C, Kuchler J, Gebauer N, et al. The addition of chloroquine and bevacizumab to plain radiochemotherapy for recurrent glioblastoma multiforme. Br J Neurosurg. 2024;38:404–10.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide mixed with normal therapy for sufferers with newly recognized glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 examine): a multicentre, randomised, open-label, part 3 trial. Lancet Oncol. 2014;15:1100–8.
Batchelor TT, Received M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, et al. NRG/RTOG 0837: Randomized, part II, double-blind, placebo-controlled trial of chemoradiation with or with out cediranib in newly recognized glioblastoma. Neurooncol Adv. 2023;5:vdad116.
Yoon WS, Chang JH, Kim JH, Kim YJ, Jung TY, Yoo H, et al. Efficacy and security of metformin plus low-dose temozolomide in sufferers with recurrent or refractory glioblastoma: a randomized, potential, multicenter, double-blind, managed, part 2 trial (KNOG-1501 examine). Discov Oncol. 2023;14:90.
Brenner AJ, Floyd J, Fichtel L, Michalek J, Kanakia KP, Huang S, et al. Section 2 trial of hypoxia activated evofosfamide (TH302) for therapy of recurrent bevacizumab-refractory glioblastoma. Sci Rep. 2021;11:2306.
Lodi A, Pandey R, Chiou J, Bhattacharya A, Huang S, Pan X, et al. Circulating metabolites related to tumor hypoxia and early response to therapy in bevacizumab-refractory glioblastoma after mixed bevacizumab and evofosfamide. Entrance Oncol. 2022;12:900082.
Towner RA, Saunders D, Lerner M, Silasi Mansat R, Yuan T, Barber D, et al. Short-term opening of the blood-brain barrier with the nitrone compound OKN-007. Am J Nucl Med Mol Imaging. 2021;11:363–73.
Towner RA, Smith N, Saunders D, Brown CA, Cai X, Ziegler J, et al. OKN-007 Will increase temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Progress. Transl Oncol. 2019;12:320–35.
Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible issue 1 pathway. Most cancers Res. 2005;65:605–12.
Abbaszade Z, Bagca BG, Avci CB. Molecular organic investigation of temozolomide and KC7F2 mixture in U87MG glioma cell line. Gene. 2021;776:145445.
Berges R, Denicolai E, Tchoghandjian A, Baeza-Kallee N, Honore S, Figarella-Branger D, et al. Proscillaridin A exerts anti-tumor results via GSK3beta activation and alteration of microtubule dynamics in glioblastoma. Cell Dying Dis. 2018;9:984.
Lan YL, Chen C, Wang X, Lou JC, Xing JS, Zou S, et al. Gamabufotalin induces a damaging suggestions loop connecting ATP1A3 expression and the AQP4 pathway to advertise temozolomide sensitivity in glioblastoma cells by focusing on the amino acid Thr794. Cell Prolif. 2020;53:e12732.
Terzioglu-Usak S, Nalli A, Elibol B, Ozek E, Hatiboglu MA. Anvirzel(TM)regulates cell loss of life via inhibiting GSK-3 exercise in human U87 glioma cells. Neurol Res. 2020;42:68–75.
Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, et al. The connection between expression of PD-L1 and HIF-1alpha in glioma cells underneath hypoxia. J Hematol Oncol. 2021;14:92.
Perez T, Berges R, Maccario H, Oddoux S, Honore S. Low concentrations of vorinostat lower EB1 expression in GBM cells and have an effect on microtubule dynamics, cell survival and migration. Oncotarget. 2021;12:304–15.
Rampazzo E, Manfreda L, Bresolin S, Cani A, Mariotto E, Bortolozzi R, et al. Histone deacetylase inhibitors impair glioblastoma cell motility and proliferation. Cancers. 2022;14:1897.
Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, et al. HDAC inhibitors elicit metabolic reprogramming by focusing on super-enhancers in glioblastoma fashions. J Clin Make investments. 2020;130:3699–716.
Pratap UP, Sareddy GR, Liu Z, Venkata PP, Liu J, Tang W, et al. Histone deacetylase inhibitors improve estrogen receptor beta expression and increase agonist-mediated tumor suppression in glioblastoma. Neurooncol Adv. 2021;3:vdab099.
Bernstock JD, Ye D, Gessler FA, Lee YJ, Peruzzotti-Jametti L, Baumgarten P, et al. Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters each mobile replication and metabolic programming. Sci Rep. 2017;7:7425.
Mo ZT, Li WN, Zhai YR, Gao SY. The results of icariin on the expression of HIF-1alpha, HSP-60 and HSP-70 in PC12 cells suffered from oxygen-glucose deprivation-induced harm. Pharm Biol. 2017;55:848–52.
Li H, Liang Q, Wang L. Icaritin inhibits glioblastoma cell viability and glycolysis by blocking the IL-6/Stat3 pathway. J Cell Biochem. 2019;120:7257–64.
Xu B, Jiang C, Han H, Liu H, Tang M, Liu L, et al. Icaritin inhibits the invasion and epithelial-to-mesenchymal transition of glioblastoma cells by focusing on EMMPRIN by way of PTEN/AKt/HIF-1alpha signalling. Clin Exp Pharm Physiol. 2015;42:1296–307.
Mangraviti A, Raghavan T, Volpin F, Skuli N, Gullotti D, Zhou J, et al. HIF-1alpha-targeting acriflavine offers long run survival and radiological tumor response in mind most cancers remedy. Sci Rep. 2017;7:14978.
Ma S, Wang F, Dong J, Wang N, Tao S, Du J, et al. Inhibition of hypoxia-inducible issue 1 by acriflavine renders glioblastoma delicate for photodynamic remedy. J Photochem Photobio B. 2022;234:112537.
Peng G, Wang Y, Ge P, Bailey C, Zhang P, Zhang D, et al. The HIF1alpha-PDGFD-PDGFRalpha axis controls glioblastoma progress at normoxia/mild-hypoxia and confers sensitivity to focused remedy by echinomycin. J Exp Clin Most cancers Res. 2021;40:278.
Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, et al. Arylsulfonamide KCN1 inhibits in vivo glioma progress and interferes with HIF signaling by disrupting HIF-1alpha interplay with cofactors p300/CBP. Clin Most cancers Res. 2012;18:6623–33.
